RXi Pharmaceuticals to Present at the 2013 ARVO Annual Meeting

  RXi Pharmaceuticals to Present at the 2013 ARVO Annual Meeting

2013 ARVO Annual Meeting

Business Wire

WESTBOROUGH, Mass. -- April 30, 2013

RXi Pharmaceuticals Corporation (OTC: RXII), a biotechnology company focused
on discovering, developing and commercializing innovative therapies addressing
major unmet medical needs using RNA-targeted technologies, today announced
that the Company will be presenting an overview of the use of sd-rxRNAs® in
the eye and highlighting specifically RXi’s work in the areas of
retinoblastoma and proliferative vitreoretinopathy at the 2013 ARVO (
Association for Research in Vision and Ophthalmology) Annual Meeting.

On Monday, May 6, 2013 at 9:45 am PDT, Michael Byrne, Ph.D., of RXi
Pharmaceuticals, will deliver a speaker presentation entitled “Development of
sd-rxRNA for Retinoblastoma Therapy” during the Retinoblastoma: Pre-Clinical
Models and Targeted Therapies session. Dr. Byrne’s presentation will be
available on the Company's website.

On Thursday, May 9, 2013, 10:30-12:15 PDT, Dr. Byrne, along with collaborators
Steven K. Fisher, Ph.D. and Geoffrey P. Lewis, Ph.D. from UCSB (University of
California, Santa Barbara), will present a poster entitled “Novel Anti-CTGF
RNAi Therapy for Treatment of Proliferative Vitreoretinopathy (PVR) and other
Ocular Disorders” during the Proliferative Vitreoretinopathy session. The
poster will be available on the Company’s website.

This conference is being held May 5-9, 2013 at the Washington State Convention
Center, Seattle, WA. For more information visit: http://www.arvo.org

About RXi Pharmaceuticals Corporation

RXi Pharmaceuticals Corporation (OTC: RXII) is a biotechnology company focused
on discovering, developing and commercializing innovative therapies based on
its proprietary, self-delivering RNAi platform. Therapeutics that use RNA
interference, or “RNAi,” have great promise because of their ability to
down-regulate, the expression of a specific gene that may be over-expressed in
a disease condition. Building on the pioneering work of scientific founder and
Nobel Laureate Dr. Craig Mello, a member of the RXi Scientific Advisory Board,
RXi’s first RNAi product candidate, RXI-109, targets connective tissue growth
factor (CTGF) to reduce dermal scarring (fibrosis), entered into human
clinical trials in June 2012. For more information, please visit

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. Such statements include,
but are not limited to, statements about future expectations, planned and
future development of RXi Pharmaceuticals Corporation’s products and
technologies. Forward-looking statements about expectations and development
plans of RXi’s products involve significant risks, and uncertainties: risks
that RXi may not be able to successfully develop its candidates, or that
development of RNAi-based therapeutics may be delayed or not proceed as
planned, or that we may not develop any RNAi-based product; risks that the
development process for our product candidates may be delayed, risks related
to development and commercialization of products by our competitors, risks
related to our ability to control timing and terms of collaborations with
third parties, and the possibility that other companies or organizations may
assert patent rights preventing us from developing our products. Actual
results may differ from those contemplated by these forward-looking
statements. RXi does not undertake to update forward-looking statements to
reflect a change in its views, events or circumstances that occur after the
date of this release.


RXi Pharmaceuticals Corporation
Tamara McGrillen, 508-929-3646
Press spacebar to pause and continue. Press esc to stop.